Efficacy and safety of premixed insulin analogs in Asian patients with type 2 diabetes: A systematic review
Authors:
Open Access
- 31 March 2017
- journal article
- review article
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 8 (4) , 518-534
Abstract
Aims/Introduction: The primary aim of this systematic review was to provide an overview of the efficacy and safety of premixed insulin analogs in Asians, specifically East Asians, with type 2 diabetes.Material and Methods: The MEDLINE, Embase, Cochrane Library and ClinicalTrials.gov databases were searched from 1 January 1995 to 26 November 2015. Randomized controlled trials involving East Asians with type 2 diabetes treated with any premixed insulin analog were included. Major comparator treatments were basal insulin and basal–bolus insulin. Comparisons were also made between East Asian and Caucasian patients. The primary efficacy outcome was glycated hemoglobin change from baseline to end‐point. The primary safety outcome was the incidence of hypoglycemia.Results: A total of 21 studies were included; most (n = 14) were carried out in China or Japan. The duration of treatment ranged from 12 to 48 weeks. The glycated hemoglobin mean/least squares mean change from baseline to end‐point after treatment with premixed insulin analogs ranged from −0.12 to −4.2% (improvement was generally more pronounced with insulin initiation vs intensification). The incidence of hypoglycemia ranged from 8.3 to 72.0% in most studies, with the variability reflecting the definition of hypoglycemia used. Efficacy and safety outcomes for premixed insulin analogs were generally similar to those for basal or basal–bolus insulin. Limited evidence suggests that dosing, efficacy and safety profiles might differ slightly between East Asian and Caucasians receiving premixed insulin analogs.Conclusions: These results support the current use of premixed insulin analogs for managing East Asian patients with type 2 diabetes.Keywords
This publication has 31 references indexed in Scilit:
- Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectablesBMC Public Health, 2013
- Factors influencing initial choice of insulin therapy in a large international non‐interventional study of people with type 2 diabetesDiabetes, Obesity and Metabolism, 2012
- Trends in prevalence of diabetes in Asian countriesWorld Journal of Diabetes, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Globalization of DiabetesDiabetes Care, 2011
- Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoringDiabetes/Metabolism Research and Reviews, 2010
- Comparison of twice‐daily injections of biphasic insulin lispro and basal‐bolus therapy: glycaemic control and quality‐of‐life of insulin‐naïve type 2 diabetic patientsDiabetes, Obesity and Metabolism, 2008
- Biphasic Insulin Aspart 30 Three Times Daily Is More Effective Than a Twice-Daily Regimen, Without Increasing Hypoglycemia, in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes DrugsDiabetes Care, 2008
- Prospective randomized study for optimal insulin therapy in type 2 diabetic patients with secondary failureCardiovascular Diabetology, 2008
- Initiating Insulin Therapy in Type 2 DiabetesDiabetes Care, 2005